Applications of GloboH hexasaccharide, linker compound, protein conjugate and immunogenic composition in treatment or inhibition of epithelial tumors
Globo H hexa sugar and carrier protein are connected through amide condensation and combined with adjuvant to form a stable sugar-protein conjugate, which solves the problems of many side reactions and poor immunogenicity in the prior art, significantly improving tumors The immunity effect of the vaccine.
Patent Information
- Application Number
- CN202411420005.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing Globo H sugar-protein coupling strategy has problems such as many side reactions, poor immunogenicity and poor stability, which limits the immune effect of tumor vaccines.
Globo H hexa sugar and carrier protein are connected by amide condensation, and stable sugar-protein conjugates are formed through a biactivated ester linker, and combined with adjuvants to form an immunogenic composition to improve immune response.
It improves the humoral and cellular immune response, produces high titers of IgG and IgM antibodies, significantly enhances the specific binding and killing effect on tumor cells, and improves the immune effect of the vaccine.
Smart Images

Figure CN118903397A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical biotechnology, and in particular to the use of GloboH hexasaccharide, linker compounds, protein conjugates and immunogenic compositions in treating or inhibiting epithelial tumors. Background Art
[0002] Abnormal tumor glycosylation is an important hallmark in cancer biology. The overexpression of tumor-associated carbohydrate antigens (TACAs) on the surface of tumor cells is in sharp contrast to the lack of / low expression in normal cells. The study of related carbohydrate antigens is also the focus of current tumor therapeutic antibodies and therapeutic vaccines. TACA globular serine glycan (Globo H) is a complex hexasaccharide compound. Globo H antigen is overexpressed in various epithelial cell tumors (such as breast, ovarian, colon, gastric, pancreatic and lung cancer) and is extremely low in normal cells. It mainly promotes cancer through tumor immunosuppression, microangiogenesis and tumor protein kinases. These findings make Globo H, a hexasaccharide antigen epitope, a compelling tumor marker and a viable target for cancer vaccine development.
[0003] The development of therapeutic vaccines or drugs targeting Globo H is expected to block these cancer-promoting mechanisms by activating the human immune system, especially activating specific antibodies and cellular immune responses against Globo H. Since tumor-associated sugar antigens have a small molecular weight, lack size effect and cluster effect, have strong immunogenicity, can only stimulate B cells to produce low-affinity IgM antibodies, and have no immune memory, they need to be coupled with carrier proteins to form sugar conjugates to induce the body to produce persistent and enhanceable IgG antibodies.
[0004] The sugar-protein coupling strategy is extremely critical to the final therapeutic vaccine effect. The existing Globo H uses the following sugar-protein coupling strategies: 1) Reductive amination method: The reaction conditions are harsh, which changes the basic structure of the antigen and is accompanied by over-reduction and other side reactions [1]; 2) Sulfur addition method: Sulfur-containing bonds are unstable in the body environment and are easily reduced or oxidized, affecting the long-term stability of the coupling product [2]; 3) Disulfide bond method: Disulfide bonds are highly reducing and have the risk of breaking in the body [3]; 4) Cycloaddition method: The cyclic linker unit may have immunogenicity problems [4]. The existing technology has low sugar-protein binding efficiency and is prone to other side reactions or immune side effects, which limits the immune effect of the existing Globo H vaccine.
[0005] In view of this, the present invention is proposed.
[0006] References: [1] Gildersleeve, J., Oyelaran, O., Simpson, J.,&Allred, B. E.(2008). Improved procedure for direct coupling of carbohydrates to proteinsvia reductive amination. Bioconjugate Chemistry, 19(7), 1485-1490. [2] Smith, A. M.,&Brown, S. P. (2015). Thiol-Mediated Conjugation ofSugars to Proteins. Bioconjugate Chemistry, 26(3), 531-540. [3] Sadowsky, J., Pillow, T. H., Chen, J., Fan, F., He, C., Wang, Y.,...&Wai, J. (2017). Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates:Application to THIOMAB Antibody-Drug Conjugates. Bioconjugate Chemistry, 28(8), 2086-2098. [4] Bruins, J. J., Blanco-Ania, D., van der Doef, V., van Delft, F.V.,&Albada, B. (2018). Orthogonal, dual protein labelling by tandemcycloaddition of strained alkenes and alkynes to ortho-quinones and azides.Chemical Communications, 54(53), 7338-7341. Summary of the Invention The purpose of the present invention is to provide the use of GloboH hexasaccharide, linker compound, protein conjugate and immunogenic composition in treating or inhibiting epithelial tumors to solve the above technical problems.
[0007] In a first aspect, the present invention provides a use of a compound of formula I or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts in the preparation of a drug or vaccine for treating or inhibiting the growth of epithelial tumors. .
[0008] In a second aspect, the present invention provides an application of a linker compound in the preparation of a drug or vaccine for treating or inhibiting the growth of an epithelial tumor, wherein the linker compound comprises a double activated ester linker and a compound of Formula I or a stereoisomer, solvate, hydrate, prodrug, stable isotope derivative, and pharmaceutically acceptable salt thereof, wherein the double activated ester linker is condensed with an aminoamide of the compound of Formula I; .
[0009] In a third aspect, the present invention provides an application of a protein conjugate in the preparation of a drug or vaccine for treating or inhibiting the growth of epithelial tumors. The protein conjugate comprises a carrier protein and the above-mentioned linker compound, and the carrier protein and the linker compound are condensed by amide.
[0010] In a fourth aspect, the present invention provides an immunogenic composition comprising the above-mentioned protein conjugate and an adjuvant.
[0011] In a fifth aspect, the present invention provides the use of the above-mentioned immunogenic composition in the preparation of a drug for treating or inhibiting the growth of epithelial tumors.
[0012] The present invention has the following beneficial effects: The sugar-protein coupling of the present invention is based on amide condensation, which has the technical advantages of small side effects, strong biocompatibility, and no additional immunogenicity. GloboH hexasaccharide can be compounded with a carrier protein through a linker to prepare a drug or vaccine for treating cancer or inhibiting the growth of epithelial tumors. By combining with an adjuvant, a corresponding immunogenic composition is prepared. Through immunological detection, a higher humoral immunity and cellular immunity effect can be produced in the subject, and a higher antibody titer of IgG, IgM, and IgG antibody subtypes can be induced in the subject. After the immunogenic composition provided by the present invention immunizes the subject, the antibody produced has a specific binding effect on tumor cells, and the CDC reaction triggered by the specific antibody has a strong killing effect on tumor cells. Therefore, the GloboH hexasaccharide, linker compound, and protein conjugate provided by the present invention have good application prospects in the preparation of drugs or vaccines for inhibiting epithelial tumors. The immunogenic composition after the protein conjugate is combined with an adjuvant also has good application prospects in the preparation of vaccines for inhibiting epithelial tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0014] Figure 1 This is a statistical graph of the weight of mice in each group injected with GloboH vaccine with different adjuvant combinations; Figure 2 This is a statistical graph of serum IgG antibody titers in mice injected with GloboH vaccines with different adjuvant combinations; Figure 3 This is a statistical graph of serum IgM antibody titers in mice injected with GloboH vaccines with different adjuvant combinations; Figure 4 The statistical results of antibody titers of IgG subtypes in the serum of mice injected with GloboH vaccines with different adjuvant combinations; Figure 5 This is a diagram showing the specific binding effect of serum antibodies on tumor cells in mice injected with GloboH vaccines with different adjuvant combinations; Figure 6 The statistical results of CDC response of serum antibodies of mice injected with GloboH vaccine with different adjuvant combinations to MCF-7 and B16F10; Figure 7 The H NMR spectrum of the compound of formula I provided in the embodiment of the present invention; Figure 8 The NMR carbon spectrum of the compound represented by Formula I provided in the embodiment of the present invention; Fig. 9 The MALDI-TOF spectrum of Globo H-CRM197 provided in the embodiment of the present invention; Fig.10 This is the MALDI-TOF spectrum of the protein conjugate (GloboH-BSA) prepared in Example 2. DETAILED DESCRIPTION
[0015] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.
[0016] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a skilled artisan. This technique is fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (PCR: The Polymerase Chain Reaction) (Academic Press, Inc.); Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.
[0017] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0018] In a first aspect, the present invention provides a use of a compound of formula I or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts in the preparation of a drug or vaccine for treating or inhibiting the growth of epithelial tumors. .
[0019] GloboH hexasaccharide can be complexed with carrier proteins through linkers to prepare drugs or vaccines for treating cancer or inhibiting the growth of epithelial tumors. By combining with adjuvants, corresponding immunogenic compositions can be prepared. Through immune detection, higher humoral and cellular immune effects can be produced in the subjects, and higher antibody titers of IgG, IgM, and IgG antibody subtypes can be induced in the subjects. The production of high antibody titers helps to improve the tumor inhibition effect.
[0020] The forms of the above-mentioned drugs or vaccines include but are not limited to: solid, liquid or semi-solid.
[0021] In a preferred embodiment of the present invention, the epithelial tumor is selected from at least one of papilloma, gastrointestinal cancer, uterine cancer, ovarian cancer, cervical cancer, lung cancer, adenocarcinoma, breast cancer, adenoma and squamous cell carcinoma.
[0022] Gastrointestinal cancer is selected from esophageal cancer, gallbladder cancer, gastric cancer, liver cancer, pancreatic cancer, bile duct cancer, small intestine cancer, colon cancer, rectal cancer, colorectal cancer and anal cancer. Colorectal tumors include one or more of polypoid type, stricture type and ulcer type.
[0023] In an alternative embodiment, adenocarcinoma includes but is not limited to lung adenocarcinoma, thyroid cancer, salivary gland cancer, pancreatic cancer or prostate cancer.
[0024] In an alternative embodiment, the adenoma includes but is not limited to a cystadenoma, a fibroadenoma, a pleomorphic adenoma or a polypoid adenoma.
[0025] In an alternative embodiment, breast cancer includes but is not limited to breast epithelial cancer; Preferably, the breast cancer is ductal carcinoma or lobular carcinoma.
[0026] Breast cancer, preferably stage II to IV and / or poorly differentiated invasive ductal carcinoma, comedo carcinoma, and medullary carcinoma (preferably grade 2).
[0027] Ovarian cancer, serous and mucinous carcinomas (preferably stages Ic to IIIb), granulosa cell tumors, surface epithelial-stromal tumors (adenocarcinomas), cystadenocarcinomas, and endometrioid tumors.
[0028] Uterine cancer, preferably including endometrioid adenocarcinoma (preferably stage I to IIIc).
[0029] Bladder cancer, preferably including transitional cell carcinoma (preferably stage II to IV).
[0030] Lung cancer, preferably includes small cell lung cancer (preferably stage I to IIIb), non-small cell lung cancer (preferably poorly to moderately differentiated squamous and adenocarcinoma) and large cell lung cancer.
[0031] The squamous cell carcinoma is one or more of oral squamous cell carcinoma, pharyngeal squamous cell carcinoma, laryngeal cancer, esophageal squamous cell carcinoma (eg esophageal squamous cell carcinoma), lip squamous cell carcinoma, uterine squamous cell carcinoma, vaginal squamous cell carcinoma and skin squamous cell carcinoma.
[0032] Oral squamous cell carcinoma (OSCC) is also called oral squamous cell carcinoma. Examples of oral squamous cell carcinoma include but are not limited to tongue squamous cell carcinoma.
[0033] In other embodiments, the squamous cell carcinoma may also be squamous cell carcinoma formed by squamous metaplasia in the bronchus, bladder, renal pelvis and other parts.
[0034] In a preferred embodiment of the present invention, the drug or vaccine is used to induce the production of at least one of the following antibodies: IgM antibodies and IgG antibodies. Drugs or vaccines can induce subjects to produce strong humoral and cellular immune responses.
[0035] The drug is used to induce the production of at least one of the following antibodies: IgG1, IgG2a, IgG2b and IgG3. For example, IgG2a can induce stronger CDC and ADCC reactions in the subject, and IgG1 can induce stronger CDC, ADCC and ADCP reactions in the subject.
[0036] In a second aspect, the present invention provides an application of a linker compound in the preparation of a drug or vaccine for treating or inhibiting the growth of an epithelial tumor, wherein the linker compound comprises a double activated ester linker and a compound of Formula I or a stereoisomer, solvate, hydrate, prodrug, stable isotope derivative, and pharmaceutically acceptable salt thereof, wherein the double activated ester linker is condensed with an aminoamide of the compound of Formula I; .
[0037] In a preferred embodiment of the present invention, the diactivated ester linker is selected from the compounds represented by the following structural formula: .
[0038] The linker compound is selected from the compounds represented by the following structural formula: .
[0039] In a third aspect, the present invention provides an application of a protein conjugate in the preparation of a drug or vaccine for treating or inhibiting the growth of epithelial tumors. The protein conjugate comprises a carrier protein and the linker compound described above, wherein the carrier protein and the linker compound are condensed by amide.
[0040] In a preferred embodiment of the present invention, the carrier protein is diphtheria toxin cross-reactive material 197, diphtheria toxoid, tetanus toxoid or bovine serum albumin.
[0041] In a preferred embodiment of the present invention, the structural formula of the protein conjugate is as follows: .
[0042] In a fourth aspect, the present invention provides an immunogenic composition, which includes the above-mentioned protein conjugate and adjuvant. After the immunogenic composition provided by the present invention immunizes the subject, the antibodies produced have a specific binding effect on tumor cells, and the CDC reaction triggered by the specific antibodies has a strong killing effect on tumor cells. Therefore, the GloboH hexasaccharide, linker compound, and protein conjugate provided by the present invention have good application prospects in the preparation of drugs or vaccines for inhibiting epithelial tumors. The immunogenic composition after the protein conjugate is combined with the adjuvant also has good application prospects in the preparation of vaccines for inhibiting epithelial tumors.
[0043] An immunogenic composition refers to a substance that can induce an immune response, that is, an immunogenic composition including an antigen can stimulate specific immune cells, causing the immune cells to activate, proliferate, and differentiate, ultimately producing immune effector substances such as antibodies and sensitized lymphocytes.
[0044] In a preferred embodiment of the present invention, the adjuvant is selected from at least one of Toll-like receptor agonists, RIG-I-like receptor agonists, NOD-like receptor agonists, C-type lectin receptors, STING agonists, bacterial toxins and their derivatives, saponins, cytokines and other adjuvants; other adjuvants are selected from at least one of heat shock protein, A151, GTP-GDP, sodium fluoride, alkyl polypropylene ester polymer, dimethyl dioctadecyl quaternary ammonium bromide, liposomes, aluminum adjuvants, MF59, AS03, α-GalCer, lipopolysaccharide and RC-529 adjuvant.
[0045] Liposomes are vesicles of variable size prepared in vitro, consisting of a spherical lipid bilayer and an aqueous inner compartment. As a modern vesicular antigen delivery method, liposomes overcome the limitations of traditional antigen delivery methods and can prolong the release of vaccines. Liposomes are usually composed of various amphipathic phospholipids, such as phosphatidylcholine, phosphatidylserine, and sphingomyelin, which can be combined with other lipids (such as cholesterol) to stabilize the membrane, and the structure and surface properties of liposomes can also be regulated by lipids with negative or positive charges. As vaccine carriers, liposomes have multiple advantages, including inhibiting antigen degradation, transporting hydrophilic and lipophilic antigens, regulating antigen release, improving antigen-specific immune responses, and enhancing cellular uptake.
[0046] In an optional embodiment, the Toll-like receptor agonist is selected from at least one of CpG-ODN, CpG 1018, peptidoglycan, lipoteichoic acid, MPL, MPLA, 3-O-deacylated monophosphoryl lipid A, imiquimod, resiquimod, bacterial flagellin, MEDI9197 and Poly I: C. In addition, the Toll-like receptor agonist includes but is not limited to agonists of TLR1, TLR2, TLR4, TLR5 and TLR9.
[0047] 3D-MPL: 3-O-deacylated monophosphoryl lipid A (3D-MPL) is also known as 3-de-O-acylated monophosphoryl lipid A or 3-O-deacylated-4'-monophosphoryl lipid A. The name indicates that the 3-position of the reducing end glucosamine in monophosphoryl lipid A is deacylated. It is isolated from Salmonella minnesota ( Salmonellaminnesota ) is a heptoseless mutant of lipid A, which is chemically similar to lipid A but lacks the acid-labile phosphoryl group and the base-labile acyl group. It can activate cells of the monocyte / macrophage lineage and stimulate the release of several cytokines, including IL-1, IL-2, TNF-α, and GM-CSF.
[0048] CpG 1018 adjuvant is a TLR9 agonist that can stimulate B cells and promote humoral immunity; it can also stimulate dendritic cell activation, thereby stimulating specific T cells and producing memory cells.
[0049] CpG ODN adjuvant, namely CpG oligodeoxynucleotides (CpG ODN) refers to a class of oligonucleotide sequences with unmethylated CG dinucleotide as the core. CpG ODN can activate TLR9 receptors and is a potential vaccine adjuvant that can enhance the strength, breadth and durability of the vaccine's immune response. CpG ODN adjuvants include but are not limited to A, B, and C, namely CpG-A ODN, CpG-B ODN and CpG-C ODN; including but not limited to ODN 2216, ODN2006, and ODN 2395.
[0050] Multimeric CpG-A ODNs are primarily localized to early lysosomes, where they lead to a strong induction of IFN-α in plasmacytoid dendritic cells. Monomeric CpG-B ODNs are concentrated in late endosomal compartments and can promote cell maturation of plasmacytoid dendritic cells and B cells. CpG-C ODNs are localized to both compartments, inducing IFN-α production and cell maturation. Other structural modifications that affect the biological effects of CpG-containing sequences include linking two or more short phosphorothioate backbone CpG ODNs via non-nucleoside chemical linkers to produce linear chimeric immunomodulatory compounds and / or formulations of CpG-containing nanoparticle compounds.
[0051] The RIG-I-like receptor agonist is selected from at least one of 3pRNA and short double-stranded RNA; The NOD-like receptor agonist is selected from at least one of muramyl dipeptide and N-acetylglucosamine; The C-type lectin receptor is selected from at least one of β-glucan and trehalose diborate; The STING agonist is selected from at least one of cGAMP, c-di-AMP and c-di-GMP; cGAMP includes but is not limited to 3'-3'cGAMP and 2'-3'cGAMP.
[0052] The bacterial toxin and its derivatives are selected from at least one of cholera toxin and its subunits and Escherichia coli heat-labile enterotoxin and its subunits; Saponin is selected from at least one of QS21, tomatin and Quil-A; The cytokine is at least one selected from the group consisting of GM-CSF, IL-2, IL-12, IL-34, IL-6, IFN-γ, Flt-3 and lymphocyte chemotactic factor.
[0053] The cholera toxin subunit is selected from CTB and / or CTA, and the E. coli heat-labile enterotoxin subunit is selected from LTB.
[0054] Aluminum adjuvants include alum, aluminum hydroxide, and aluminum phosphate.
[0055] Lipopolysaccharide is a zwitterionic polysaccharide adjuvant.
[0056] The adjuvant is a combination adjuvant of QS21 and 3D-MPL; or, a combination adjuvant of QS21 and S34. After screening, the inventors found that the adjuvant combination of QS21+3D-MPL can induce higher IgG2a and IgG3 in the human body, thereby inducing a stronger anti-tumor immune response. QS21+S34 can induce better total IgG antibody titers and IgM titers in human subjects, etc. Higher total IgG antibody titers help induce stronger CDC, ADCC and ADCP reactions in the subject, thereby exerting higher anti-tumor activity.
[0057] In a fifth aspect, the present invention provides use of an immunogenic composition in the preparation of a medicament for treating or inhibiting the growth of an epithelial tumor.
[0058] The above-mentioned medicine also includes a pharmaceutically acceptable carrier.
[0059] Other pharmaceutically acceptable carriers are selected from one or more of starch, pregelatinized starch, microcrystalline cellulose, lactose, lactose starch complex, lactose cellulose complex, mannitol, mannitol starch complex, sorbitol, povidone, copovidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, cross-linked polyvidone, magnesium stearate, sodium stearyl fumarate, talc, and stearic acid.
[0060] In an optional embodiment, the above-mentioned medicine is a liquid pharmaceutical preparation (such as a kind of injection), such as a solution, a suspension and a gel usually containing a liquid carrier, such as water and / or a pharmaceutically acceptable organic solvent. In addition, such liquid preparations may also include a pH adjusting agent, an emulsifier or a dispersant, a buffer, a preservative, a wetting agent, a gelling agent (such as methylcellulose), such as defined above. The medicine may be isotonic, that is, they may have the same osmotic pressure as blood. The isotonicity of the medicine may be adjusted by using sodium chloride and other pharmaceutically acceptable agents, such as glucose, maltose, boric acid, sodium tartrate, propylene glycol and other inorganic or organic soluble substances. The viscosity of the liquid composition may be adjusted by a pharmaceutically acceptable thickener such as methylcellulose. Other suitable thickeners include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, etc. The preferred concentration of the thickener depends on the selected agent.
[0061] In a preferred embodiment of the present invention, the dosage form of the drug is selected from any one of tablets, pills, powders, suspensions, gels, emulsions, granules, capsules, injections and sprays.
[0062] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0063] Example 1 This embodiment provides a compound represented by formula I, and its structural formula is as follows: .
[0064] This embodiment also provides a method for preparing the compound represented by the above formula I, comprising: (1) Synthesis of compound A: The synthesis was carried out according to the following synthesis route: Dissolve p-methylphenylthio-β-D-pyranogalactoside in dichloromethane / pyridine (1:1, v / v), add 1.05 equivalents of di-tert-butylsilylbis(trifluoromethanesulfonic acid), and stir at room temperature for 3 hours. Cool to -20°C, add 1.05 equivalents of 9-fluorenylmethyl chloroformate, and stir for 1 hour. Add 1.2 equivalents of benzoyl chloride and stir at room temperature for 1 hour. After the reaction is completed, methanol is added to quench and concentrate. The residue is dissolved in ethyl acetate, washed with 1M hydrochloric acid solution, saturated sodium bicarbonate solution, saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (eluent: petroleum ether and ethyl acetate), and finally compound A is obtained with a yield of 89%.
[0065] The characterization data of compound A are as follows: 1 H NMR (600 MHz, CDCl 3 ) δ 8.10 (dd, J = 8.4, 1.4Hz, 1H), 7.76 – 7.69 (m, 1H), 7.60 – 7.56 (m, 1H), 7.54 (dd, J = 7.4, 1.1 Hz,1H), 7.50 – 7.44 (m, 2H), 7.41 – 7.32 (m, 4H), 7.25 – 7.21 (m, 1H), 7.11 (td,J = 7.5, 1.1 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 5.85 (t, J = 10.0 Hz, 1H), 4.91 (dd, J = 9.8, 3.1 Hz, 1H), 4.87 – 4.80 (m, 2H), 4.36 – 4.26 (m, 4H), 4.19 (t, J = 7.7 Hz, 1H), 3.56 (d, J = 2.2 Hz, 1H), 2.33 (s, 3H), 1.19 (s,9H), 1.05 (s, 9H). 13 C NMR (150MHz, CDCl 3) δ 165.42, 154.55, 143.40, 143.17,141.25, 138.25, 133.40, 133.26, 130.08, 130.07, 129.78, 129.73, 128.56,127.90, 127.26, 127.23, 125.34, 125.29, 120.03, 88.00, 78.49, 74.96, 70.53,70.46, 68.26, 67.16, 46.56, 27.66, 27.65, 23.42, 21.24, 20.84. HRMS (ESI): [M+Na] + Calculate for C 43 H 48 O 8 SSiNa, 775.2731; found, 775.2732.
[0066] (2) Synthesize compound B represented by the following structural formula: , compound A was dissolved in DMF, 1.5 equivalents of benzaldehyde dimethyl acetal and 0.3 equivalents of camphorsulfonic acid were added, and the mixture was stirred at 40°C overnight, triethylamine was added to quench and concentrated. The residue was dissolved in DMF, 5.5 equivalents of benzyl bromide and 5.5 equivalents of sodium hydride were added at 0°C, and stirred at room temperature for 3 hours. After the reaction was completed, methanol was added to quench and concentrate, and the mixture was purified by silica gel column chromatography (eluent: toluene and acetone) to obtain compound B with a yield of 78%.
[0067] The characterization data of compound B are as follows: 1 H NMR (600 MHz, CDCl 3) δ 7.57 – 7.54 (m, 2H),7.51 – 7.47 (m, 2H), 7.42 – 7.38 (m, 4H), 7.38 – 7.29 (m, 16H), 7.27 – 7.24(m, 3H), 7.22 – 7.19 (m, 3H), 5.49 (s, 1H), 5.21 (d, J = 10.6 Hz, 1H), 4.96(d, J = 11.0 Hz, 1H), 4.88 (d, J = 11.2 Hz, 1H), 4.82 (d, J = 10.7 Hz, 1H),4.79 (dd, J = 11.2, 2.6 Hz, 2H), 4.76 – 4.74 (m, 2H), 4.57 (d, J = 12.0 Hz,1H), 4.51 – 4.47 (m, 2H), 4.36 (d, J = 12.1 Hz, 1H), 4.24 (dd, J = 12.3, 1.5Hz, 1H), 4.08 – 4.04 (m, 2H), 4.01 (t, J = 9.3 Hz, 1H), 3.91 (dd, J = 10.9,4.1 Hz, 1H), 3.87 (dd, J = 12.4, 1.9 Hz, 1H), 3.83 – 3.78 (m, 2H), 3.76 –3.70 (m, 3H), 3.68 (d, J = 9.0 Hz, 1H), 3.66 – 3.63 (m, 2H), 3.48 (dd, J =9.2, 7.8 Hz, 1H), 3.46 – 3.38 (m, 2H), 3.34 – 3.25 (m, 2H), 2.96 (d, J = 1.3Hz, 1H)。 13 C NMR (150 MHz, CDCl 3) δ 139.07, 138.95, 138.93, 138.61, 138.52,138.21, 128.94, 128.69, 128.46, 128.35, 128.32, 128.29, 128.20, 128.18,128.03, 127.86, 127.79, 127.70, 127.58, 127.54, 127.48, 127.35, 126.65,103.92, 102.94, 101.44, 83.07, 81.83, 79.76, 78.91, 77.66, 75.86, 75.39,75.18, 74.90, 73.75, 73.07, 71.71, 70.58, 70.05, 69.15, 69.05, 68.39, 66.44,50.77. HRMS (ESI): [M+NH 4 ] + Calculate for C 58 H 67 N 4 O 12 , 1011.4750; found, 1011.4748.
[0068] (3) Synthesize compound C represented by the following structural formula: , compound B was dissolved in tetrahydrofuran, 4 equivalents of borane-trimethylamine complex was added, 6 equivalents of aluminum chloride and 2 equivalents of water were added under ice bath, and stirred at room temperature for 3 hours. After the reaction was completed, ethyl acetate was added for dilution, washed with 1M hydrochloric acid solution, dried with anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (eluent: toluene and acetone) to obtain compound C with a yield of 79%.
[0069] The characterization data of compound C are as follows: 1 H NMR (600 MHz, CDCl 3) δ 7.44 – 7.40 (m, 2H),7.39 – 7.22 (m, 28H), 5.01 (d, J = 10.8 Hz, 1H), 4.94 (d, J = 11.1 Hz, 1H),4.83 – 4.75 (m, 4H), 4.74 (d, J = 11.8 Hz, 1H), 4.69 (d, J = 11.8 Hz, 1H),4.58 (d, J = 12.1 Hz, 1H), 4.50 – 4.45 (m, 3H), 4.44 – 4.39 (m, 2H), 4.07 –4.03 (m, 2H), 4.00 (t, J = 9.4 Hz, 1H), 3.85 – 3.78 (m, 2H), 3.76 – 3.71 (m,3H), 3.71 – 3.67 (m, 2H), 3.66 – 3.59 (m, 4H), 3.51 (dd, J = 9.7, 5.3 Hz,1H), 3.45 (dd, J = 9.2, 7.8 Hz, 1H), 3.43 – 3.38 (m, 2H), 3.37 – 3.33 (m,1H), 3.33 – 3.26 (m, 2H)。 13 C NMR (150 MHz, CDCl 3 ) δ 139.19, 138.87, 138.71,138.37, 138.28, 138.02, 128.54, 128.44, 128.35, 128.34, 128.18, 128.12,128.01, 127.93, 127.88, 127.84, 127.73, 127.71, 127.68, 127.61, 127.58,127.56, 127.31, 103.88, 102.60, 82.89, 81.76, 81.19, 79.46, 76.59, 75.41,75.32, 75.16, 74.83, 73.58, 73.21, 72.87, 72.09, 70.56, 70.03, 69.11, 68.54,68.35, 66.23, 50.76; HRMS (ESI): [M+Na] + calcd for C 58 H 65 N 3 O 12Na, 1018.4460; found, 1018.4463.
[0070] (4) Synthesizing compound D; The synthesis was carried out according to the following synthesis route: 1.5 equivalents of compound A donor and 1 equivalent of compound C acceptor were dissolved in toluene, molecular sieves were added and stirred for 30 minutes, 3 equivalents of N-iodosuccinimide and 0.5 equivalents of tert-butyldimethylsilyl trifluoromethanesulfonate were added under cooling to 0°C, a small amount of pyridine and methanol were added to quench after stirring at low temperature for 5 hours, and 10V of triethylamine was added and stirred at room temperature for 3 hours. After the reaction was completed, the mixture was filtered, concentrated, and purified by silica gel column chromatography (eluent: acetone and petroleum ether) to obtain compound D with a yield of 83%.
[0071] The characterization data of compound D are as follows: 1 H NMR (600 MHz, CDCl 3) δ 8.02 – 7.99 (m, 2H),7.43 – 7.39 (m, 1H), 7.31 – 7.22 (m, 18H), 7.22 – 7.13 (m, 12H), 7.04 – 6.99(m, 2H), 5.43 (dd, J = 10.3, 3.5 Hz, 1H), 5.17 (d, J = 3.5 Hz, 1H), 4.90 (d,J = 11.0 Hz, 1H), 4.86 (d, J = 12.3 Hz, 1H), 4.82 – 4.75 (m, 2H), 4.72 – 4.66(m, 3H), 4.59 (d, J = 12.2 Hz, 1H), 4.48 (d, J = 12.1 Hz, 1H), 4.42 (d, J =7.7 Hz, 1H), 4.40 (d, J = 7.7 Hz, 1H), 4.38 (dd, J = 3.4, 1.2 Hz, 1H), 4.33(d, J = 12.1 Hz, 1H), 4.21 – 4.20 (m, 1H), 4.14 (dd, J = 10.3, 3.4 Hz, 1H),4.06 (d, J = 3.0 Hz, 1H), 4.04 – 3.97 (m, 3H), 3.92 (t, J = 9.2 Hz, 1H), 3.78– 3.69 (m, 5H), 3.68 – 3.64 (m, 3H), 3.60 – 3.56 (m, 4H), 3.56 – 3.52 (m,2H), 3.41 (dd, J = 9.0, 7.7 Hz, 1H), 3.37 – 3.32 (m, 1H), 3.26 – 3.22 (m,3H), 3.22 – 3.17 (m, 2H), 1.09 (s, 9H), 1.00 (s, 9H); 13 C NMR (125 MHz, CDCl 3)δ 167.00, 139.12, 138.80, 138.52, 138.40, 138.14, 138.09, 137.57, 133.21,130.19, 129.94, 129.73, 128.62, 128.52, 128.50, 128.47, 128.36, 128.31,128.27, 128.21, 128.17, 128.14, 128.09, 128.06, 128.03, 127.94, 127.87,127.83, 127.78, 127.72, 127.68, 127.62, 127.59, 127.43, 127.25, 127.12,103.84, 102.98, 98.31, 81.92, 81.86, 80.88, 79.06, 77.36, 76.99, 75.07,74.96, 74.79, 74.72, 74.35, 74.04, 73.42, 73.24, 73.20, 73.06, 72.97, 72.53,71.91, 70.59, 70.05, 69.17, 69.11, 68.65, 68.51, 68.45, 67.41, 66.90, 66.76,50.78, 27.62, 27.47, 23.41, 20.90; HRMS (ESI): [M+Na] + Calculate for C 79 H 95 N 3 O 18 SiNa,1424.6272; found, 1424.6267.
[0072] (5) Synthesis of compound E: The synthesis was carried out according to the following synthesis route: , 1.5 equivalents of trichloroimidate donor and 1 equivalent of thioglycoside acceptor were dissolved in dichloromethane / toluene (1:1, v / v), molecular sieves were added and stirred for 30 minutes, and 0.3 equivalents of trifluoromethanesulfonic acid were added after cooling to 0°C. Stir at low temperature for 3 hours. After the reaction was completed, triethylamine was added to quench, filtered, concentrated, and purified by silica gel column chromatography (eluent: acetone and petroleum ether) to obtain compound E with a yield of 76%.
[0073] The characterization data of compound E are as follows: 1 H NMR (600 MHz, CDCl 3) δ 7.57 – 7.53 (m, 2H),7.44 – 7.34 (m, 3H), 7.16 – 7.12 (m, 1H), 7.09 (d, J = 7.9 Hz, 2H), 5.52 (s,1H), 5.48 (d, J = 7.2 Hz, 1H), 5.36 (dd, J = 3.6, 1.2 Hz, 1H), 5.20 (dd, J =10.4, 7.9 Hz, 1H), 5.07 (d, J = 10.1 Hz, 1H), 4.96 (dd, J = 10.4, 3.5 Hz,1H), 4.79 (d, J = 8.0 Hz, 1H), 4.75 (d, J = 12.0 Hz, 1H), 4.70 (d, J = 12.0Hz, 1H), 4.45 (dd, J = 10.8, 3.3 Hz, 1H), 4.30 (d, J = 3.2 Hz, 1H), 4.19 –4.08 (m, 3H), 3.93 (dd, J = 12.2, 1.6 Hz, 1H), 3.89 – 3.83 (m, 1H), 3.74 –3.64 (m, 1H), 3.32 (s, 1H), 2.56 (s, 6H), 2.15 (s, 3H), 2.07 (s, 3H), 2.05(s, 3H), 1.97 (s, 3H); 13 C NMR (150 MHz, CDCl 3 ) δ 169.88, 169.81, 169.60,168.85, 153.29, 144.08, 137.50, 129.97, 128.57, 128.53, 127.77, 127.68,125.85, 100.99, 100.26, 94.70, 85.59, 75.90, 75.61, 74.09, 70.44, 70.37,69.07, 68.87, 68.43, 66.56, 61.11, 52.82, 22.13, 20.30, 20.26, 20.24, 20.08.HRMS (ESI): [M+Na] + calcd for C 38 H 44 Cl 3 NO 15 SNa, 914.1389; found, 914.1385。
[0074] (6) Synthesis of compound F: The synthesis was carried out according to the following synthesis route: 1.5 equivalents of compound E donor and 1 equivalent of compound D acceptor were dissolved in dichloromethane / toluene (1:1, v / v), molecular sieves were added and stirred for 30 minutes, cooled to -50°C, 3 equivalents of N-iodosuccinimide and 0.3 equivalents of trifluoromethanesulfonic acid were added, and stirred at -50°C for 3 hours. After the reaction was completed, triethylamine was added to quench, filtered, concentrated, and purified by silica gel column chromatography (eluent: acetone and petroleum ether) to obtain compound F with a yield of 76%.
[0075] The characterization data of compound F are as follows: 1 H NMR (500 MHz, CDCl 3) δ 8.25 – 8.19 (m, 2H),7.59 – 7.54 (m, 1H), 7.51 – 7.46 (m, 5H), 7.40 – 7.23 (m, 32H), 7.22 – 7.17(m, 6H), 7.06 – 7.01 (m, 2H), 5.76 (dd, J = 10.7, 3.7 Hz, 1H), 5.48 (s, 1H),5.33 (d, J = 3.5 Hz, 1H), 5.29 – 5.22 (m, 2H), 5.13 (dd, J = 10.4, 7.9 Hz,1H), 5.00 (d, J = 7.9 Hz, 1H), 4.96 (d, J = 11.1 Hz, 1H), 4.88 (d, J = 12.1Hz, 1H), 4.86 – 4.79 (m, 3H), 4.78 – 4.70 (m, 5H), 4.65 – 4.57 (m, 4H), 4.49(d, J = 12.1 Hz, 1H), 4.44 (d, J = 7.6 Hz, 1H), 4.41 (d, J = 7.6 Hz, 1H),4.38 – 4.28 (m, 5H), 4.26 (s, 1H), 4.19 – 4.11 (m, 4H), 4.11 – 4.07 (m, 2H),4.05 – 4.00 (m, 2H), 3.99 – 3.91 (m, 3H), 3.91 – 3.85 (m, 4H), 3.85 – 3.80(m, 2H), 3.80 – 3.74 (m, 2H), 3.74 – 3.67 (m, 5H), 3.67 – 3.64 (m, 1H), 3.64– 3.61 (m, 2H), 3.54 (t, J = 8.8 Hz, 1H), 3.48 (d, J = 8.1 Hz, 1H), 3.46 –3.40 (m, 2H), 3.37 – 3.31 (m, 2H), 3.31 – 3.25 (m, 4H), 3.16 (dd, J = 8.7,5.5 Hz, 1H), 3.06 (dd, J = 9.1, 5.4 Hz, 1H), 2.84 (t, J = 6.2 Hz, 2H), 2.15(s, 3H), 2.06 (s, 3H), 2.00 (s, 3H), 1.95 (s, 3H), 1.14 (s, 9H), 0.97 (s,9H);13 C NMR (125 MHz, CDCl 3 ) δ 170.38, 170.35, 170.02, 169.42, 165.92, 153.40,139.25, 138.71, 138.65, 138.26, 138.08, 138.02, 137.54, 133.53, 130.61,129.80, 128.93, 128.84, 128.42, 128.33, 128.29, 128.26, 128.21, 128.15,128.07, 128.03, 127.83, 127.80, 127.68, 127.60, 127.53, 127.51, 127.46,127.20, 126.50, 103.75, 102.69, 101.75, 100.80, 99.55, 98.31, 95.45, 82.00,80.89, 80.66, 79.45, 77.36, 76.02, 75.85, 75.02, 74.84, 74.56, 74.32, 73.63,73.12, 72.97, 72.84, 72.31, 70.88, 70.68, 70.54, 69.99, 69.86, 69.02, 68.64,67.76, 67.00, 65.86, 61.38, 54.36, 50.72, 27.54, 23.33, 20.89, 20.80, 20.76,20.56; HRMS (ESI): [M+Na] + Calculate for C 109 H 129 Cl 3 N 4 O 33 SiNa, 2177.7266; found, 2177.7250.
[0076] (7) Synthesis of compound G: The synthesis was carried out according to the following synthesis route: , Compound F was dissolved in tetrahydrofuran / pyridine hydrofluoride (2:1, v / v), stirred at room temperature overnight, then diluted with ether, washed with copper sulfate solution, saturated sodium bicarbonate solution, and saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated. The residue was dissolved in tetrahydrofuran / 1M sodium hydroxide solution (3:1, v / v), stirred at room temperature overnight, adjusted to neutrality with hydrogen resin, filtered, extracted, and concentrated. The residue was dissolved in methanol / triethylamine / acetic anhydride (12:2:1, v / v / v), stirred at room temperature for 3 hours, filtered, and concentrated. The residue was dissolved in n-butanol / water (1:1, v / v), palladium carbon was added, and hydrogenation was performed to debenzylate. After the reaction was completed, it was filtered, concentrated, and purified by exclusion chromatography (BioGel P-2, 45-90μm, eluent: 0.1M ammonium bicarbonate solution), and the eluent containing the product was combined and lyophilized to obtain compound G (79%).
[0077] The characterization data of compound G are as follows: 1 H NMR (600 MHz, D 2 O) δ 4.90 (d, J = 4.0 Hz,1H), 4.68 (d, J = 8.4 Hz, 1H), 4.53 (d, J = 8.1 Hz, 1H), 4.50 (d, J = 7.8 Hz,1H), 4.44 (d, J = 7.8 Hz, 1H), 4.37 (t, J = 6.6 Hz, 1H), 4.24 – 4.23 (m, 1H), 4.17 (d, J = 3.2 Hz, 1H), 4.10 – 4.06 (m, 2H), 4.05 – 4.01 (m, 2H), 4.01 –3.94 (m, 2H), 3.93 – 3.87 (m, 4H), 3.87 – 3.80 (m, 4H), 3.80 – 3.72 (m, 11H), 3.71 – 3.66 (m, 4H), 3.66 – 3.62 (m, 3H), 3.62 – 3.55 (m, 4H), 3.51 (dd, J =9.9, 7.7 Hz, 1H), 3.35 – 3.30 (m, 1H), 3.21 (t, J = 5.1 Hz, 2H), 2.01 (s,3H); 13 C NMR (150 MHz, D 2O) δ 174.65, 104.34, 102.82, 102.43, 101.55, 99.90,79.08, 78.18, 76.68, 74.99, 74.51, 74.34, 74.12, 73.99, 72.40, 71.95, 70.37,70.09, 69.77, 69.11, 68.45, 68.07, 67.49, 67.10, 65.91, 60.51, 60.46, 59.85,59.47, 51.00, 38.59, 21.77.
[0078] (8) Synthesize the compound represented by formula I: 1 equivalent of compound G, 1.5 equivalents of guanosine diphosphate-L-fucose (GDP-Fuc) and 2 equivalents of magnesium chloride were dissolved in 0.1M Tris-HCl buffer, alkaline phosphatase (CIAP, 1 U / µL) and fucosyltransferase (α1,2FucT, 1 mg / mL) were added, and the mixture was incubated at 37°C for 16 hours and the reaction progress was monitored by mass spectrometry. After the reaction was complete, centrifugation was performed and purified by exclusion chromatography (BioGel P-2, 45−90μm, eluent: 0.1M ammonium bicarbonate solution), and the eluents containing the product were combined and lyophilized to obtain compound I (87%).
[0079] In summary, the overall synthetic route is shown below:
[0080] Among them, Step 1 corresponds to the above step (4), Step 2 corresponds to the above step (6), Step 3 corresponds to the above step (7), and Step 4 corresponds to the above step (8).
[0081] The characterization spectrum of the compound shown in Formula I is shown in Figure 7 and Figure 8 , characterization data: 1 H NMR (600 MHz, D 2O) δ5.21 (d, J = 4.1 Hz, 1H), 4.87 (d, J = 4.0 Hz, 1H), 4.60 (d, J = 7.7 Hz, 1H), 4.54 – 4.51 (m, 2H), 4.50 (d, J = 7.8 Hz, 1H), 4.37 (t, J = 6.6 Hz, 1H), 4.24– 4.19 (m, 2H), 4.09 – 4.05 (m, 2H), 4.01 (d, J = 3.2 Hz, 1H), 4.00 – 3.95(m, 3H), 3.95 – 3.91 (m, 2H), 3.90 – 3.84 (m, 4H), 3.84 – 3.81 (m, 3H), 3.81– 3.80 (m, 1H), 3.79 – 3.71 (m, 12H), 3.70 – 3.66 (m, 4H), 3.66 – 3.60 (m,6H), 3.60 – 3.55 (m, 2H), 3.32 (t, J = 8.5 Hz, 1H), 3.16 (t, J = 5.1 Hz, 2H), 2.03 (s, 3H), 1.20 (d, J = 6.6 Hz, 3H); 13 C NMR (150 MHz, D 2 O) δ 174.28,103.96, 103.30, 102.02, 100.41, 99.26, 78.65, 78.22, 77.11, 76.32, 76.08,75.48, 75.04, 74.79, 74.59, 74.44, 73.54, 72.87, 72.06, 71.82, 70.81, 70.10,69.55, 69.48, 69.16, 69.08, 68.90, 68.45, 67.99, 67.80, 66.91, 66.76, 60.92,60.32, 59.94, 51.61, 39.11, 23.21, 22.20, 15.28.
[0082] This embodiment provides a protein conjugate (GloboH+CRM 197 ), comprising: synthesizing according to the following synthesis path: , 3 mg (one equivalent) of Formula I and three equivalents of PNP activated diester were stirred at room temperature for 2 hours in ten times the amount of triethylamine. TLC showed that the reaction was complete. The reaction solution was concentrated and chromatographed on a C18 reversed phase column to obtain Globo H-linker (Formula II), i.e., linker compound, with a yield of 95%.
[0083] Globo H-linker (Formula II) (3 mg) and CRM197 (2 mg) were dissolved in PBS buffer (320 μL, 100 mM, pH 7.4) and incubated at room temperature for 16 hours. The reaction solution was purified using a 0.5 mL centrifugal filter membrane (Amicon® Ultra-0.5 10 Kd), eluent: ultrapure water 300 μL × 3, centrifugation conditions: 12000 r × 5 min.
[0084] According to MALDI-TOF analysis ( Fig. 9 ), CRM197 peaks at m / z 58710.416, and the highest peak of Globo H-CRM197 is at m / z 63669.512. Calculation shows that each carrier protein CRM197 carries an average of 4.1 oligosaccharide units.
[0085] Example 2 This example provides a method for preparing a protein conjugate (GloboH-BSA), wherein Globo H-linker (Formula II) (3 mg) and BSA (2 mg) are dissolved in PBS buffer (320 μL, 100 mM, pH 7.4), incubated at room temperature for 16 hours, and the reaction solution is purified using a 0.5 mL centrifugal filter membrane (Amicon® Ultra-0.5 10 Kd), eluent: ultrapure water 300 μL × 3, centrifugation conditions: 12000 r × 5 min, to form GloboH-BSA glycoprotein. According to MALDI-TOF analysis ( Fig.10 ), BSA peaks at m / z 66889.351, and the highest peak of Globo H-BSA is at m / z 81603.957. Through calculation, it can be known that the average number of Globo H hexasaccharides on each BSA is: n=(81603.957-66889.351) / 1212.47=12.14 ≈12.
[0086] Example 3 This example provides a method for preparing different adjuvant combinations, and the specific steps are as follows: 1. Preparation of blank liposomes: Dissolve 0.2 g DOPC in 0.5 mL chloroform and dissolve until clear; (2) Dissolve 0.05 g cholesterol in 0.5 mL chloroform and dissolve until clear. Then combine the above two solutions and mix them evenly with an adjustable vortex mixer; use a rotary evaporator at a water bath temperature of 40°C, a speed of 60 rpm, and a vacuum pressure of 0.04 MPa to evaporate into a thin film; adjust the pH of 10mM PBS to 6.8, preheat it at 40°C after adjustment, take 50 mL PBS and add it to the thin film after rotary evaporation, and vortex and oscillate evenly; then use a high shear disperser to shear the mixed solution at 12000 rpm for 5-10 minutes, and control the shear time with a particle size analyzer; then disperse the above samples in a high-pressure homogenizer, and homogenize them under a pressure of 15000psi-20000psi to obtain a nanoliposome solution. After passing the particle size instrument test, filter through 0.45μm and 0.22μm pinhole filter membranes to obtain a liposome injection solution.
[0087] 2. Preparation of AL adjuvant: Prepare 100 mL of 1 mol / L sodium hydroxide solution, 4100 mL of 0.21% potassium aluminum sulfate solution, and 3800 mL of 0.005 mol / L PBS solution, mix the three in a container, let it settle overnight, remove the supernatant, re-add the buffer solution to resuspend, let it settle again, repeat the operation 5 times, and finally make up the volume to 8 L with the buffer solution, and divide it for standby use; 3. Preparation of S34 liposomes or 3D-MPL liposomes Dissolve 0.2 g of DOPC in 0.5 mL of chloroform, (2) dissolve 0.05 g of cholesterol in 0.5 mL of chloroform, and (3) dissolve 2 mg of S34 or 10 mg of 3D-MPL in 1 mL of chloroform. Then the three solutions were combined and vortexed evenly; the solution was vortexed into a thin film by a rotary evaporator at a water bath temperature of 40°C, a rotation speed of 60 rpm, and a vacuum pressure of 0.04 MPa; the pH of PBS was adjusted to 6.8, and after adjustment, it was preheated at 40°C, and 50 mL of PBS was added to the thin film after vortexing, and vortexed evenly; the mixed solution was sheared at 12000 rpm for 5-10 minutes by a high shear disperser, and the shearing time was controlled by a particle size analyzer; the above samples were dispersed in a high-pressure homogenizer, and homogenized at a pressure of 15000psi-20000psi to obtain a nanoliposome solution, and after passing the particle size instrument test, the solution was filtered through a 0.45 micron and 0.22 micron pinhole filter membrane to obtain a liposome injection solution; 4. Preparation of QS21 adjuvant: Dissolve 1 g of DOPC in 5 mL of deionized water to obtain the QS21 adjuvant solution.
[0088] Example 4 Effects of Globo H vaccine with different adjuvant combinations on body weight of mice.
[0089] Experimental methods: SPF female Balb / C mice aged 6 to 8 weeks were used. The mice were grouped according to Table 1, and divided into 8 groups, with 10 mice in each group. The adjuvant and vaccine were vortexed for 30 seconds before injection. Immunization was performed subcutaneously on the back according to the schedule of 1, 14, and 28 days. The body weight was recorded during the process. The specific doses of the vaccine (or immunogenic composition) injected were as follows: Group 1 was injected with 5 μg / antigen (Globo H-CRM197) + 35 μL liposome solution; Group 2 was injected with 5 μg antigen (Globo H-CRM197) + 100 μg Al adjuvant (aluminum hydroxide); Group 3 was injected with 5 μg antigen (Globo H-CRM197) + 10 μg 3D-MPL adjuvant; Group 4 was injected with 5 μg antigen (Globo H-CRM197) + 10 μg QS-21 adjuvant; Group 5 was injected with 5 μg antigen (Globo H-CRM197) + 2 μg S34 adjuvant; Group 6 was injected with 5 μg antigen (Globo H-CRM197) + 2 μg S34 adjuvant + 10 μg QS-21 adjuvant; Group 7 was injected with 5 μg antigen (Globo H-CRM197) + 10 μg 3D-MPL adjuvant + 10 μg QS-21 adjuvant; Group 8 was injected with 5 μg antigen (Globo H-CRM197) + 2 μg S34 adjuvant + 10 μg QS-21 adjuvant.
[0090] Table 1. Grouping of GloboH vaccines with different adjuvant combinations
[0091] Experimental results: from Figure 1 The results show that there is no significant difference in body weight among the eight groups of mice. After three immunizations, the weight of mice slightly increased with age, and different Globo H vaccines had no significant effect on the weight of mice. This result shows that the safety of Globo H antigen combined with different adjuvants is relatively good.
[0092] Example 5 Effects of GloboH vaccines with different adjuvant combinations on IgG antibody titers in mice.
[0093] Experimental methods: 6-8 week old SPF female Balb / C mice were used, 10 mice per group, and grouping and immunization were performed according to the procedure in Example 3. Blood was collected from the mouse orbits on the 14th, 28th and 42nd days, and the IgG antibody content in the serum of different groups of mice was detected by ELISA. The ELISA detection method is as follows: First, GloboH-BSA glycoprotein was prepared according to the preparation method of the protein conjugate (GloboH-BSA) in Example 2, and used to coat the ELISA plate to detect anti-GloboH antibodies in the serum to exclude the situation that the antibodies produced are directed against CRM97 rather than GloboH. The GloboH-BSA antigen was diluted to 1ug / mL with PBS, coated at 100μL / well, and incubated at 4°C overnight. Wash three times with PBST, 250μL / well, then add 2% BSA solution prepared with PBS, and incubate at room temperature for 2 hours. The serum to be tested was diluted with diluent (1% BSA / PBST) in proportion. Pour out the blocking solution, add the diluted serum to be tested, and incubate at room temperature for two hours. Wash three times with PBST, add diluted HRP-labeled secondary antibody (abcam, catalog number 31430), 100 μL / well, incubate at room temperature for 1 hour. Wash five times with PBST, add TMB colorimetric solution 100 μL / well, incubate at room temperature in the dark for 10-15 minutes. Add 1M HCl, 100 μL / well. Read OD within 15 minutes 450 value.
[0094] The experimental data were expressed as mean ± standard deviation and analyzed statistically using SPSS Statistics software. The t-test was used to compare the means of two groups, and the one-way analysis of variance was used to compare the means of multiple groups. ns means no significant difference, *P<0.05, **P<0.01, ***P<0.001.
[0095] Experimental results: The results are as follows Figure 2 After 3 injections, except for group 1, the antibody titers of all groups were higher than those of group 2, indicating that the antibody production effect was best after 3 injections. In addition, the IgG antibody titer of group 6 GloboH+QS21+S34 was the highest, indicating that the adjuvant combination of QS21+S34 was better in producing total IgG antibodies.
[0096] Example 6 Effects of GloboH vaccines with different adjuvant combinations on IgM antibody titers in mice.
[0097] Experimental methods: 6-8 week old SPF female Balb / C mice were used, 10 mice in each group, and grouping and immunization were performed according to the procedure in Example 4. On the 13th day after the third immunization, the different groups of mice were respectively bled by orbital blood, and the IgM antibody content in the serum of the different groups of mice was detected by ELISA. ELISA detection and statistical analysis were performed according to the experimental method of Example 5, except that the antibody subtype detected was different (the antibody was from Sangon Biotechnology, D110103-0001), and the other detection steps were completely the same.
[0098] The results are as follows Figure 3 Among several composite adjuvants, the adjuvant combination of QS21+S34 has the best effect in producing IgM antibodies. In addition to the composite adjuvant of QS21+S34, QS21 has the best effect in inducing the production of IgM among single adjuvants.
[0099] Example 7 Effects of GloboH vaccines with different adjuvant combinations on mouse IgG subtypes.
[0100] Experimental methods: 6-8 week old SPF female Balb / C mice were used, 10 mice in each group, and grouping and immunization were performed according to the procedure in Example 4. On the 13th day after the third immunization, blood was collected from the eye sockets of different groups of mice, and the contents of IgG1 (antibody from Invitrogene, PA1-74421), IgG2a (antibody from Invitrogene, A10685), IgG2b (antibody from Invitrogene, M32407) and IgG3 (antibody from Invitrogene, M32607) antibodies in the serum of different groups of mice were detected by ELISA. ELISA detection and statistical analysis were performed according to the experimental method of Example 5, except that the antibody subtypes detected were different, and the other detection steps were completely the same.
[0101] Experimental results: The results are as follows Figure 4 , IgG1 produced by group 6 GloboH QS21+S34 group ( Figure 4 The results of Figure a in Figure 2 were higher than those of Group 7 GloboHQS21+3D-MPL, Group 8 GloboH S34+3D-MPL, Group 4 GloboH QS21 and Group 5 GloboH S34, indicating that the QS21+S34 adjuvant system can induce stronger CDC, ADCC and ADCP responses in the human body. The IgG2a ( Figure 4 b) and IgG3 ( Figure 4d in the figure) was significantly higher than those in group 6 GloboH QS21+S34, group 8 GloboH S34+3D-MPL, group 4 GloboH QS21 and group 3 GloboH 3D-MPL. IgG2a can induce strong CDC and ADCC reactions in mice, indicating that QS21+3D-MPL can induce strong cellular immune responses in mice. IgG2b ( Figure 4 (c) is slightly higher than group 7 QS21+3D-MPL. Although IgG2b can induce CDC response in mice, the effect is far less strong than that of IgG2a. This once again shows that group 7 QS21+3D-MPL can induce strong CDC and ADCC responses in mice.
[0102] Example 8 This example tests the ability of antibodies produced by GloboH vaccines with different adjuvant combinations to specifically bind to MCF7 breast cancer cells.
[0103] Experimental methods: 6-8 week old SPF female Balb / C mice were used, 10 mice in each group, and grouped and immunized according to the procedure in Example 4. On the 7th day after the third immunization, blood was collected from the eye sockets of the mice in different groups. Statistical analysis was performed according to Example 5.
[0104] MCF-7 breast cancer cells are a type of tumor cell that highly expresses GloboH antigen, while B16F10 melanoma cells are a type of tumor cell that lowly expresses GloboH antigen. As negative controls, both cells are from the American type culture collection. Collect logarithmic growth MCF-7 and B16F10 cells, centrifuge at 350-500g for 5 minutes, wash twice with 1×PBS, and discard the supernatant. Centrifuge at 350-500g for 5 minutes, discard the supernatant. Wash with 1×PBS, centrifuge at 350-500g for 5 minutes, discard the supernatant, and repeat three times. Resuspend the cells with 2% BSA, and each 100uL of blocking solution contains 1×10 6Cells, block at 4℃ and avoid light for 30~60 minutes. Centrifuge at 350~500g for 5 minutes and discard the supernatant. Wash with 1×PBS, centrifuge at 350~500g for 5 minutes, discard the supernatant, add 1×PBS to resuspend the cells, and each 100uL of blocking solution contains 1×106 cells. Add appropriate amount of primary antibody according to the recommended concentration of the antibody (1:20 dilution of mouse serum in different adjuvant combination groups), incubate at 4℃ and avoid light for 45 minutes~1 hour. Wash with 1×PBS, centrifuge at 350~500g for 5 minutes, discard the supernatant, and repeat once. Resuspend the cells with fluorescently labeled secondary antibody, select the appropriate dilution multiple according to the antibody requirements, and incubate at 4℃ and avoid light for 45 minutes~1 hour. Centrifuge at 350~500g for 5 minutes and discard the supernatant. Wash with 1×PBS, centrifuge at 350~500g for 5 minutes, and discard the supernatant. Resuspend the cells with PBS, the volume is about 200~500uL, and analyze by flow cytometry. This method is to detect the amount of antibodies in the serum antibodies of each group of mice that can specifically bind to MCF-7 cells, so as to evaluate the strength of tumor-specific immune response induced by different GloboH vaccines.
[0105] Experimental results: The mouse serum on the 7th day after 3 injections of immunization was co-incubated with MCF-7 breast cancer cells that highly expressed GloboH, and then labeled with fluorescent secondary antibodies, and the binding of specific antibodies in the serum to MCF-7 cells was detected by flow cytometry. B16F10 cells were used as negative control, and the results showed that ( Figure 5 ), Group 7 GloboH QS21+3D-MPL group's mouse serum antibodies had the best binding effect with MCF-7 cells, indicating that the antibodies induced by QS21+3D-MPL had the strongest specific killing ability against MCF-7 breast cancer cells, that is, the best anti-tumor effect.
[0106] Example 9 Effects of GloboH vaccine with different adjuvant combinations on inducing CDC response in mice.
[0107] Experimental methods: 6-8 week old SPF female Balb / C mice were used, 10 mice in each group, and grouped and immunized according to the procedure in Example 4. On the 13th day after the third immunization, orbital blood was collected from mice in different groups. Statistical analysis was performed according to Example 5.
[0108] MCF-7 cells were trypsinized and resuspended in DMEM complete medium to 4 × 10 5 / mL; 100 μL of cell suspension was transferred to a 96-well plate and cultured overnight to allow the cells to completely adhere to the wall; the old culture medium was discarded, and the serum samples of mice in each group were diluted with DMEM complete culture medium to 5% serum samples, which were added to the corresponding wells of the 96-well plate. The control group was added with the same volume of DMEM complete culture medium and incubated together for 24 hours. Gently washed twice with DMEM complete culture medium, 100 μL each time; 100 μL of 2% suckling rabbit complement (Cedarlane, CL3441-R) (diluted with DMEM complete culture medium) was added, and incubated at 37°C for 6h; CCK8 kit (Biyuntian, C0038) was used for color development, and the results were detected on an ELISA reader (450 nm). This method is to detect the difference in the complement-mediated cell killing effect of serum antibodies in each group of mice.
[0109] calculate: CDC%=100*(1-(Ae-Amax) / (Amin-Amax)) Where Ae represents the absorbance value of the experimental group wells at 450 nm, Amax represents the absorbance value of the maximum killing group wells at 450 nm, and Amin represents the absorbance value of the minimum killing group wells at 450 nm.
[0110] Experimental results: On the 13th day after the third immunization, the mouse serum was collected to detect the killing ability of the CDC reaction of the specific antibodies in the serum on MCF-7 cells. The results showed that the number of MCF-7 cells surviving in group 7 Globo H QS21+3D-MPL was the lowest ( Figure 6 ), indicating that it induced the strongest CDC reaction, which is consistent with the result that GloboH QS21+3D-MPL can induce the production of a large amount of IgG2a and IgG3.
[0111] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Use of a compound of formula I or its stereoisomers, solvates, hydrates, prodrugs, stable isotope derivatives and pharmaceutically acceptable salts in the preparation of a drug or vaccine for treating or inhibiting the growth of epithelial tumors, characterized in that: 。 2. The use according to claim 1, characterized in that: The epithelial tumor is selected from at least one of papilloma, gastrointestinal cancer, uterine cancer, ovarian cancer, cervical cancer, lung cancer, adenocarcinoma, breast cancer, adenoma and squamous cell carcinoma.
3. The use according to claim 1, characterized in that: The drug or vaccine is used to induce the production of at least one of the following antibodies: IgM antibodies and IgG antibodies.
4. Use of a linker compound in the preparation of a drug or vaccine for treating or inhibiting the growth of epithelial tumors, characterized in that: The linker compound includes a double activated ester linker and a compound of Formula I or a stereoisomer, solvate, hydrate, prodrug, stable isotope derivative and pharmaceutically acceptable salt thereof, wherein the double activated ester linker is condensed with an aminoamide of the compound of Formula I; 。 5. The use according to claim 4, characterized in that: The diactivated ester linker is selected from the compounds represented by the following structural formula: ; The linker compound is selected from the compounds represented by the following structural formula: 。 6. Use of a protein conjugate in the preparation of a drug or vaccine for treating or inhibiting the growth of epithelial tumors, characterized in that: The protein conjugate comprises a carrier protein and the linker compound described in any one of claims 4 to 5, wherein the carrier protein and the linker compound are condensed by amide.
7. The use according to claim 6, characterized in that: The carrier protein is diphtheria toxin cross-reactive material 197, diphtheria toxoid, tetanus toxoid or bovine serum albumin.
8. An immunogenic composition, characterized in that It comprises the protein conjugate according to any one of claims 6 to 7 and an adjuvant.
9. The immunogenic composition according to claim 8, characterized in that The adjuvant is selected from at least one of Toll-like receptor agonists, RIG-I-like receptor agonists, NOD-like receptor agonists, C-type lectin receptors, STING agonists, bacterial toxins and derivatives thereof, saponins, cytokines and other adjuvants; the other adjuvants are selected from at least one of heat shock protein, A151, GTP-GDP, sodium fluoride, alkyl polypropylene ester polymer, dimethyl dioctadecyl quaternary ammonium bromide, liposomes, aluminum adjuvants, MF59, AS03, α-GalCer, lipopolysaccharide and RC-529 adjuvants.
10. Use of the immunogenic composition according to any one of claims 8 to 9 in the preparation of a medicament for treating or inhibiting the growth of epithelial tumors.
Citation Information
Patent Citations
Combination vaccines with low dose of hib conjugate
CN102028944A
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
CN109379889A
Glycoprotein entrapped immune agonist conjugate vaccine and application of glycoprotein entrapped immune agonist conjugate vaccine in vaccine preparation
CN118236479A
Immunogenic composition and use thereof
TW201328705A
Glycan arrays and method of use
US20170067885A1
